Results 191 to 200 of about 80,637 (252)

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, Volume 159, Issue 8, Page 1857-1872, 15 October 2026.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Immune-checkpoint inhibitor-induced bullous pemphigoid in patients with metastatic renal cell carcinoma: two case reports and systematic review of the literature. [PDF]

Acta Oncol
Filis P, Lindskog M, Curman P, Kuzmina N, Krantz Å, Chatzidionysiou K, Costa Svedman F, Zerdes I.   +7 more
europepmc   +1 more source

Occurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz, Martin Ebinger, Michaela Döring, Markus Mezger, Ursula Holzer, Rupert Handgretinger, Peter Lang, Manon Queudeville   +7 more
wiley   +1 more source

Immunotherapy Rechallenge in HCC: A Second Chance for Response? [PDF]

Liver Int
Da Fonseca LG, Guerrero A, Muñoz-Martínez SG.   +2 more
europepmc   +1 more source

Progression‐free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta‐analysis

Cancer, Volume 132, Issue 19, 1 October 2026.
ABSTRACT The objective of this systematic review and meta‐analysis was to evaluate the validity of progression‐free survival (PFS) and the objective response rate (ORR) as surrogate end points for overall survival (OS) in randomized controlled trials (RCTs) of metastatic renal cell carcinoma.
Russell Leong, David Chen, Laith Almasri, Nicholas Lum, Karren Xiao, Maryam Soleimani, Christian K. Kollmannsberger, Srinivas Raman   +7 more
wiley   +1 more source

Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. [PDF]

JAMA
Chaft JE, Sun Z, Rudin CM, Khullar OV, Simone CB, Oettel K, Kozono D, Sunkara R, Faller B, Isbell JM, Hugec V, Shipstone A, McGary EC, Clarke JM, Talsania A, Ding L, Govindan R, Sands JM, Heymach JV, Raez LE, Malik SM, Stinchcombe TE, Mandrekar SJ, Bradley J, Gerber DE, Vokes E, Gandara D, Staley C, Ramalingam SS.   +28 more
europepmc   +1 more source

Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1129-1141, October 2026.
Despite the immunomodulatory mechanism of immune checkpoint inhibitors (ICIs), systemic glucocorticoids are commonly used in advanced non–small cell lung cancer (NSCLC). Evidence regarding their effects on ICI outcomes is inconsistent, in part due to confounding by indication and immortal time bias.
Da Eun Lee, Geunho Lim, Minoh Ko, Mari Kim, Ji Sun Chun, Borim Lee, Miso Kim, Kwangsoo Kim, Byung Kwan Choi, Jeongmin Seo, Jin Hyoung Kang, Taehoon Ko, In‐Wha Kim, Jung Mi Oh   +13 more
wiley   +1 more source

IMMU-NO versus yes: Applicability of immune checkpoint inhibitors in gynecologic cancers. [PDF]

Cancer
Manning WB, Youssef AM, Yeku OO.
europepmc   +1 more source

Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study

Head &Neck, Volume 48, Issue 10, Page 2810-2820, October 2026.
ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange, Mathilde Morisseau, Justin Michel, Thibaut Reverdy, Sylvain Morinière, Amaury Daste, Maxime Humbert, Caroline Viala, Pauline Corbaux, Tiffany Darbas, François‐Régis Ferrand, Valentin Favier, Camille Evrard, Diane Evrard, Delphine Farneti, Sarah Betrian‐Lagarde, Victor Sarradin   +16 more
wiley   +1 more source

Immune Checkpoint Inhibitors in Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL): A Case Report and Review of the Literature. [PDF]

Cancer Rep (Hoboken)
Klenner C, Singer J.
europepmc   +1 more source